PRESS RELEASE
Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023
Orion will publish Financial Statement Release for 2022 on Thursday,
Webcast and conference call
A webcast and a conference call for analysts, investors and media representatives will be held on Thursday,
A link to the live webcast is available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.
Confenrence call can be joined by registering through the following link:
http://palvelu.flik.fi/teleconference/?id=1009425
Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.
Questions can also be presented in writing through the question form of the webcast.
Silent period
The silent period preceding the publication is ongoing and continues until the disclosure.
Contact person:
tel. +358 10 426 2721
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to
![](https://ml-eu.globenewswire.com/media/YjIzYTJkZTUtNTM5Mi00ZDBiLTgzNmMtZTRiMTc2MDg3NjZlLTEwMTM1MzY=/tiny/Orion-Oyj.png)
© OMX, source